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Abstract
Background: Adequate organ function and good performance status (PS) are common eligibility criteria for phase I trials. As
inflammation is pathogenic and prognostic in cancer we investigated the prognostic performance of inflammation-based
indices including the neutrophil (NLR) and platelet to lymphocyte ratio (PLR).
Methods: We studied inflammatory scores in 118 unselected referrals. NLR normalization was recalculated at disease
reassessment. Each variable was assessed for progression-free (PFS) and overall survival (OS) on uni- and multivariate
analyses and tested for 90 days survival (90DS) prediction using receiving operator curves (ROC).
Results: We included 118 patients with median OS 4.4 months, 23% PS.1. LDH$450 and NLR$5 were multivariate
predictors of OS (p,0.001). NLR normalization predicted for longer OS (p,0.001) and PFS (p,0.05). PS and NLR ranked as
most accurate predictors of both 90DS with area under ROC values of 0.66 and 0.64, and OS with c-score of 0.69 and 0.60.
The combination of NLR+PS increased prognostic accuracy to 0.72. The NLR was externally validated in a cohort of 126
subjects.
Conclusions: We identified the NLR as a validated and objective index to improve patient selection for experimental
therapies, with its normalization following treatment predicting for a survival benefit of 7 months. Prospective validation of
the NLR is warranted.
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Introduction
The safety of individuals participating into phase I oncology
studies is of paramount importance, where potentially high-risk
investigational medicinal products (IMP) are administered for the
first time in patients who may have limited life expectancy [1].
Stringent eligibility criteria are pre-defined to avoid the
exposure of frail patients to potentially harmful or ineffective
experimental treatments, as well as to protect trial results from
possible inconsistencies in the assessment of the safety and
tolerability of the IMP.
Despite this, the eligibility assessment of phase I candidates
varies significantly as a function of the study protocol and relies
mostly on subjective clinical parameters such as performance
status (PS) and predicted life expectancy [2]. Although poor PS is a
known predictor of mortality in cancer patients, concerns have
been raised as to its true reliability in oncology trial patients [3]
and there is disagreement as to whether subjects with ‘‘interme-
diate impairment’’ of their PS (ie. scoring PS= 2) can be safely
offered the option of experimental treatments.
For these reasons, increasing research efforts have been made to
qualify novel and more objective prognostic determinants in the
phase I oncology patient population. A number of prognostic
models have been proposed to improve the eligibility assessment
and better predict their survival [4]. These models variously
encompass predictors of worse outcome such as hypoalbumin-
emia, high tumour burden, elevated serum lactate dehydrogenase
(LDH), lymphopenia as well as advanced PS [5,6,7,8,9].
However, there is substantial disagreement as to the optimal
prognostic score as a result of the retrospective nature of some of
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the published studies and because of the lack of independent
validation of the proposed algorithms [10]. Moreover, most of the
studies inferring the utility of a given score in the screening process
of phase I candidates have derived their prognostic information
only from patients who actually received an IMP [11,12] as
opposed to unselected referrals prior to trial recruitment. As only
about 30% of patients referred for phase I trials are ultimately
offered treatment [13], this approach may have biased the
screening of variables, limiting the generalizability of their
prognostic power to the broader population of phase I referrals.
As a result, none of the proposed prognostic scores are routinely
incorporated in the design of phase I study protocols.
A second limitation of these scores is their inability to be
dynamically used throughout the course of treatment to estimate
treatment induced benefits and stratify individuals according to
response. This is of greater consequence in early phase trials, as
the qualification of reliable predictive markers of response may not
only lead to a clearer identification of the 30–50% of patients
achieving disease control following experimental treatments
[7,12], but also improve the detection of early pharmacodynamic
effects, with major positive implications in the optimal dose
selection of the tested compounds [14]. With many novel therapies
causing disease stabilization without altering overall tumour size,
there is a requirement for alternative methods for assessing IMP
activity.
Inflammation is a critical component in the pathogenesis [15] as
well as in the progression of cancer [16]. The presence of an acute
phase reaction is a common event in cancer patients and results
from the excess of pro-inflammatory cytokines such as interleukins
(IL-1, IL-6, IL-8), tumour necrosis factor alpha (TNF-a) and
interferons [17]. This systemic inflammatory response, that is
deemed to reflect both disease activity as well as the host’s innate
response towards the tumour, has a causative role in determining
most of the constitutional symptoms and signs reported by cancer
patients including weight loss, anorexia, fatigue and cancer related
anemia [18]. Systemic inflammation can be easily and reproduc-
ibly quantified in patients using a number of prognostic indices
such as the neutrophil to lymphocyte (NLR) and platelet to
lymphocyte ratio (PLR), both derived from inflammation-induced
derangements in the full blood count.
The deterioration of these scores is a reliable predictor of
survival in most solid tumors [19], independent of stage and
histological subtype [20]. Moreover, treatment induced changes of
the NLR have recently been qualified as predictors of response to
treatment across different tumour types [21,22,23]. However,
these scores have never previously been assessed in the phase I
cancer population.
The aim of this study was therefore to comparatively test the
NLR and PLR for their prognostic power in a series of unselected
referrals to a phase I clinic. Additionally, we aimed to assess
whether changes in these scores calculated at the pre-defined time
of tumour reassessment can predict a significant survival
advantage in patients treated in the context of phase I oncology
trials.
Methods
We conducted a retrospective analysis of all patients referred to
the Hammersmith early phase trials unit with solid malignancies
(Wellcome Trust McMichael Clinical Research Facility,
WTMCRF) from January 2007 to December 2011. Patients were
identified through clinic lists, paper and electronic medical records
review. Complete demographic and treatment data including
gender, age, tumour type and extent of metastatic spread, previous
treatments, details of subsequent trial participation (eligibility, trial
entry date) were collected together with the complete blood count,
serum biochemical profile and PS. Clinical outcomes such as
overall survival (OS, cancer specific) and the 90-days mortality
rate (90DM) were calculated from the time of referral to our unit.
In patients who entered a phase I trial, progression-free survival
(PFS) was calculated as time from the date of the first dose of IMP
to the date of radiologically proven disease progression. Depend-
ing on protocol specific requirements, CT scan based tumour
reassessment was carried out after 6–8 weeks from study baseline.
Response to treatment was defined by a senior radiologist
according to the Response Evaluation Criteria in Solid Tumours
(RECIST 1.1) [24].
The NLR was calculated by dividing the absolute neutrophil
count by the absolute lymphocyte count. NLR$5 was considered
elevated as previously described [25]. The same calculation was
Figure 1. Study flow diagram illustrating patient disposition in the training and validation set.
doi:10.1371/journal.pone.0083279.g001
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applied to derive the PLR, with 300 being the cutoff for positivity,
in accordance with previously published literature [26]. Dynamic
changes in the biomarker were defined as NLR normalization
versus persistent abnormality as described before [22].
For a total of 8 patients participating in a phase I trial of an oral
targeted agent, pre and post-treatment 18Fluorodeoxyglucose
(FDG) positron emission tomography (PET) scans were available.
The baseline scan was taken within 28 days from dosing, whereas
follow up scans were taken following 2 cycles of treatment (8 weeks
after the first dose of the IMP). All PET readings were performed
by the same radiologist on PET-CT fused images, blinded to
clinical outcomes. Changes in maximal standardize uptake values
(SUVmax) were compared before and after treatment.
Table 1. Patient characteristics.
Training Set Validation Set
Baseline characteristic n=118 (%) Median (range) N=126 (%) Median (range)
Gender Male 39 (33) - 54 (43) -
Female 79 (67) 72 (57)
Age in years ,65 65 (55) 63 (28–80) 82 (65) 62 (39–79)
$65 53 (45) 44 (35)
ECOG Performance Status 0 33 (28) 18 (28)
1 53 (45) 83 (45)
2 20 (17) 21 (17)
3 9 (8) 4 (8)
Missing 3 (2) -
Previous treatment lines 0–2 63 (54) 2 (0–8) 75 (59) 2 (0–5)
$3 53 (46) 51 (40)
Tumour burden Locoregional disease only 10 (8) 2 (0–5) 6 (6) 2 (0–6)
1–2 distant metastatic sites 87 (74) 64 (50)
$3 distant metastatic sites 21 (18) 56 (44)
Areas of metastatic spread Liver 61 (52) 58 (46)
Lung 37 (31) 53 (42)
Bones 22 (19) 15(12)
Peritoneum 36 (30) 38 (30)
Extraregional lymphnodes 23 (20) 58 (46)
Brain 4 (3) 3 (2)
Other sites 21 (17) 19 (15)
Albumin, g/L ,35 g/L 18 (70) 33 (13–43) 103 (70) 43 (32–49)
$35 g/L 42 (30) 12 (30)
Serum LDH, IU/dL ,450 IU/dL 62 (52) 249 (46–4218) 36 (72) 264 (143–1816)
$450 IU/dL 15 (13) 14 (28)
Hemoglobin, g/L $12 g/L 49 (41) 11.5 (8.2–14.4) 68 (54) 12.3 (8.0–17.0)
,12 g/L 69 (59) 58 (46)
White blood cell count,6103/liter ,10.5 95 (80) 7.3 (2–12) 97 (77) 6.8 (4.5–20.8)
$10.5 23 (20) 29 (23)
Platelet count,6103/liter ,400 93 (79) 277 (69–626) 98 (77) 239 (98–474)
$400 25 (21) 28 (22)
Primary tumour group Gynaecological cancers 42 (35) 20 (16)
Gastrointestinal cancers 39 (33) 46 (37)
Breast cancer 18 (15) 10 (8)
Genitourinary cancers 5 (4) 9 (7)
Lung cancer/mesothelioma 4 (3) 10 (8)
Skin cancers/melanoma 4 (3) 4 (3)
Head and neck 3 (2) 23 (18)
Others 3 (2) 4 (3)
Overall Survival, months 4.4 (0.2–39.0) 3.8 (0.5–43.4)
Training and Validation Cohorts.
doi:10.1371/journal.pone.0083279.t001
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We validated the significance of the tested prognostic variables
in an independently collected set of data, using a separate cohort
of 126 patients with similar characteristics. The validation cohort
included a total of 107 patients presenting consecutively to the
early phase clinical trials unit at the University College London
Hospital (UCLH) from April 2010 to January 2012. A further set
of 19 patients treated between October 2007 and February 2009
on a trial in collaboration with the Royal Marsden Hospital Drug
Development Unit were included. A flow chart describing both
patient cohorts is shown in Figure 1.
Statistical Analysis
Pearson Chi-square test was used to assess for any associations
between categorical variables. Univariate analysis of the different
clinical factors associated with survival was carried out using
Kaplan-Meier statistics and Log-rank test. Each factor was tested
for its independent prognostic value using multivariate analysis
according to Cox proportional hazard model using SPSS statistical
package version 19 (IBM SPSS Inc., USA). A stepwise backward
approach was used and variables with a p-value greater than 0.10
were removed from the model. The concordance index method (c
index) was used to rank the different staging systems according to
their capacity of discriminating patients according to outcome
(OS). We assessed the effect of the candidate risk factors using the
Cox model using R and the Statistical Analysis System (SAS, Cary,
NC, USA) [27]. We used the rms packages of Dr Frank Harrell to
identify a subset of predictors by backward elimination [28].
Where we assessed the predictive ability of a Cox proportional
hazards model, we compared the actual survival outcomes of
usable pairs of patients with the values of their estimated
prognostic indices from the Cox model. Where the assessment of
prediction of multiple biomarkers was performed, the c index was
adjusted within the rms package for the over-optimism produced
by modeling and assessment being done on the same data via
comparison with 150 bootstrap samples. We quantified the
improvement in the predictive ability of the top ranked prognostic
score by calculating a new c index value reflecting the combination
of prognostic variables. The c index of the resulting model was
further internally validated by established bootstrapping tech-
niques using 150 iterations. The receiver operating characteristic
(ROC) curve method was used to compare the discriminative
ability of candidate variables in predicting 90DM. All p-values
presented are two-sided.
Ethics Statement
All the patients included in this retrospective study had given
explicit written consent for their information to be stored in the
hospital database and used for research. All clinical investigations
were conducted according to the principles expressed in the
Declaration of Helsinki. Official approval for the use of
retrospective data was granted by the Hammersmith Hospital
Clinical Audit Office.
Results
Demographics
One hundred and twenty six patients were identified as new
consecutive referrals to the WTMCRF at Imperial College
London. Cases with insufficient follow up (n= 2) or with previous
history of inflammatory disease or active concomitant infection at
the time of referral (n = 6) were excluded. The clinicopathological
variables describing our patient series are summarized in Table 1.
Although baseline bloods were available for all patients, albumin
was missing in 58 (49%) patients and LDH in 41 (34%) patients. In
total, 96% of the patients were evaluable for the tested prognostic
scores (NLR and PLR) whereas 98% were evaluable for ECOG
PS.
In the training set, most patients were female (67%) and had
evidence of distant metastases in at least one visceral site (91%).
Twenty-five percent of the patients were PS 1–3. At the time of
analysis 85 patients had died (72%). The cancer specific OS of the
entire cohort was 4.4 months (range 0.2–39 months) and the
overall ninety-day mortality rate was 41%. Fifty-two patients
(44%) were treated within one of 7 phase I trials, the majority
investigating molecularly targeted agents (71%). No patients were
selected on the basis of target gene/protein expression. At the
planned CT scan reassessment, one subject showed partial
response (2%), 18 had disease stabilization (35%) whereas the
remaining 33 had disease progression (63%). The median PFS in
this subgroup was 1.7 months (0.2–18.7 months), while the median
OS was 5.6 months (1.3–38.6 months).
Relationship between Inflammatory scores and patient
characteristics
According to the inflammatory scores, 36% of patients in the
training set had an abnormal NLR whereas 33% had an abnormal
PLR at baseline. At the time of disease reassessment, the NLR was
Table 2. The relationship between clinicopathological factors and baseline inflammatory scores (NLR, PLR) in patients with
advanced solid tumours considered for experimental treatments (Training Set).
Variable NLR,5 NLR$5 P PLR,300 PLR$300 P
Gender, M/F 24/46 14/29 0.85 28/46 10/29 0.19
Age, ,65/$65 34/36 29/14 0.05* 37/37 26/13 0.09
ECOG PS, 0–1/$2 61/8 24/17 ,0.001* 56/17 29/8 0.84
N of metastatic sites, ,2/$2 61/9 31/12 0.04* 63/11 29/10 0.16
Liver metastases, absent/present 38/32 17/26 0.12 36/38 19/20 0.99
Lung metastases, absent/present 50/20 26/17 0.22 50/24 26/13 0.92
Bone metastases, absent/present 61/9 32/11 0.08 60/14 33/6 0.64
LDH, ,450/$450 IU/L 42/6 20/9 0.04* 42/10 20/5 0.93
Hb, $12/,12 g/L 33/36 11/32 0.01* 34/39 10/29 0.03*
Albumin, $35/,35 g/L 35/35 9/34 0.002* 31/43 13/26 0.37
*Marks an association reaching statistical significance (p,0.05).
doi:10.1371/journal.pone.0083279.t002
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recalculated and 34% of the treated subjects showed a worsening
of their NLR index. An elevated NLR at baseline was associated
with more advanced PS (p,0.001), presence of .2 sites of
metastasis (p = 0.04), elevated LDH (p= 0.04), hypoalbuminemia
(p = 0.002), anemia (p = 0.01) and younger age (p = 0.05). An
elevated PLR was associated with anemia (p= 0.03) (Table 2).
Inflammatory scores and survival
Univariate analysis of survival revealed albumin ,35 g/L
(p,0.001), LDH$450 IU/L (p,0.001), advanced PS (p,0.001),
haemoglobin ,12 g/L (p = 0.01), number of previous systemic
lines (p = 0.02), elevated NLR (p,0.001) as well as normalization
of the NLR following treatment (p,0.001) as being significant
predictors of OS, with hypoalbuminemia (p = 0.01), high LDH
(p= 0.005), poor PS (p = 0.006), high risk NLR (p= 0.04) and
NLR normalization (p= 0.03) qualifying as independent predictors
following multivariate analysis.
Patients in whom the NLR was $5 had a median OS of 4.2
months while patients with NLR,5 had a median OS value of 7.7
months. Normalization of the NLR at disease reassessment was
associated with a 7 months improvement in OS (12.5 vs. 5.5
months) (Figure 2).
An association between LDH levels at presentation (p= 0.04)
and NLR normalization following treatment (p = 0.04) and PFS
was found and confirmed to have an independent predictive
power at multivariate analysis (p = 0.009 and 0.008 respectively)
(Table 3). Patients achieving NLR normalization at first
reassessment had a median PFS of 3.8 months, while patients in
whom the NLR remained persistently elevated or worsened
following first reassessment had a median PFS of 1.3 months.
Comparative performance of Prognostic Models
ROC curve analysis revealed ECOG PS (area under curve
(AUC) = 0.63, 95% CI 0.53–0.77, p= 0.02), baseline NLR
(AUC=0.65, 95% CI 0.54–0.76, p = 0.007) but not baseline
PLR (AUC=0.53, 95% CI 0.42–0.64, p = 0.60) to significantly
predict for 90DM (Figure 2).
The discriminatory capacity of each prognostic system was
compared by means of Harrell’s concordance index. The c-score
value was calculated for each prognostic score. ECOG PS had a c-
index score of 0.69 (95% CI 0.56–0.82), followed by the NLR 0.60
(95% CI 0.50–0.70) and PLR 0.53 (95% CI 0.42–0.64).
Improvement of the discriminatory capacity of the first ranked
prognostic variable was obtained by combining the NLR with
ECOG PS, giving rise to a new c index of 0.72 (95% CI 0.59–
0.83).
Validation of Prognostic Models
The prognostic value and discriminative ability of inflammatory
scores was further tested in an independent dataset composed of
126 patients with OS (median 3.8 months, range 0.5–43.4,
p = 0.09), ECOG PS (20% PS.1, p = 0.14) and number of
previous treatment lines (median 2, range 0–8, p = 0.34) similar to
those described for the training set. The full clinicopathological
profile of the validation cohort is described in Table 1.
In the validation set, advanced ECOG PS (HR 1.98 95% CI
1.2–3.1, p = 0.003), hypoalbuminemia (HR 4.3 95% CI 2.1–8.5,
p,0.001) and elevated NLR at the time of referral (HR 2.2 95%
CI 1.4–3.5, p = 0.001) were confirmed as univariate predictors of
survival, whereas PLR.300 (p= 0.08) and number of metastatic
sites (p = 0.69) did not retain prognostic value. Multivariate
analysis of OS revealed that elevated NLR (HR 2.84 95% CI
1.6–5.0, p,0.001), hypoalbuminemia (HR 5.11, 95% CI 2.4–10.7
p,0.001) and poorer ECOG PS (HR 1.71, 95% CI 1.0–3.1
p= 0.08) independently predicted for worse OS. The discrimina-
tory capacity of the NLR, as assessed by the c index, was 0.63
(95% CI 0.51–0.76) whereas the calculated c score for ECOG PS
was 0.65 (95% CI 0.54–0.76). An improvement in the discrim-
inative ability of PS was confirmed in the validation set when
combined with the NLR, deriving a resulting c score of 0.70 (95%
CI 0.59–0.81). As shown in Table 4, an elevated NLR predicted
for significantly worse survival outcomes in patients with preserved
as well as advanced ECOG PS in both training and validation set.
Inflammatory scores and FDG-PET response
An exploratory analysis investigating the association between
changes in the NLR following treatment and metabolic response
measured by 18FDG PET-CT was undertaken in 8 subjects in
whom pre and post treatment 18FDG PET-CT scans were used as
a pharmacodynamic endpoint. Changes in SUVmax compared
before and after treatment and are summarized in a waterfall plot,
where each column is representative of the SUVmax change in
each individual patient (Figure 3A).
All patients displaying metabolic progression of disease (3/3)
were categorized as having a persistently elevated NLR following
treatment. Conversely, the achievement of NLR normalization
was associated with an overall decrease or stability in SUVmax
values in 3/4 subjects (Figure 3B).
Discussion
Patients with advanced solid malignancies who have been
referred for consideration of phase I trial entry represent a
uniquely heterogenous population of individuals with different
types of cancer, exposure to multiple lines of previous therapy and
a life expectancy that rarely exceeds 9 months [1].
Exhaustion of standard treatments, adequate performance
status and organ function are generally the only criteria that
guide accrual into early phase trials. However these parameters
are insufficient predictors of overall survival, or as early means of
identifying patients who are deriving benefit from experimental
treatments [2].
In this study we aimed to qualify the clinical value of simple
inflammatory related scores such as the NLR and PLR both as
predictors of the overall prognosis of our patients and as dynamic
markers that could be used to stratify trial participants according
to their response to treatment.
We have shown that the NLR is an independent predictor of
OS, PFS and early mortality in an unselected series of patients
with advanced cancer referred to a phase I service. Interestingly,
our data show that patients in whom the NLR normalized at the
moment of planned disease reassessment had a survival gain of 7
months compared to individuals remaining in or worsening to the
‘‘high risk’’ category throughout treatment. This follows the
observation made across several other studies in which NLR
changes induced by treatment were an independent early
predictor of treatment benefit [21,23,29,30].
There is compelling evidence in the literature showing that the
presence of a systemic inflammatory reaction is predictive of worse
outcome in patients with cancer, independent from tumour site
and stage [20]. Among the several methods used to measure
systemic inflammation, the NLR and PLR are the most used
Figure 2. Kaplan Meier curve analysis showing that NLR$5 predicts for poor OS in the training (Panel A) and in the validation set
(Panel B). NLR normalization calculated at disease reassessment predicts for better OS (Panel C) and PFS (Panel D). Receiver operator curve for
comparison of PS, baseline NLR and PLR for predicting 90 day survival (Panel E).
doi:10.1371/journal.pone.0083279.g002
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parameters [31] in conjunction with the Glasgow Prognostic
Score (GPS) that takes into account hypoalbuminemia and
elevation of C-reactive protein (CRP) [32].
A raised NLR reflects a combined state of neutrophilia and
relative lymphopenia consequential to the systemic release of
proinflammatory cytokines by cancer cells or by the host’s
innate immune system as part of a coordinated anti-tumour
response. Lymphopenia is a known predictor of mortality in
cancer patients [33] and part of its detrimental effect on
prognosis has to be found in the impairment of the CD8+
cytotoxic immune system branch, with a consequential reduc-
tion of the immune-mediated antitumour response [34]. An
increased NLR also reflects sustained angiogenesis and prolif-
erative potential of tumour cells, two unfavorable hallmarks of
cancer [26].
In our study cohort, patients with a raised NLR had a
significantly poorer PS, higher LDH, more advanced disease
and a higher prevalence of anemia, confirming that elevation of
the NLR indicates a more aggressive clinical phenotype. This is
not an unexpected finding since the presence of a systemic
inflammatory response is known to underlie most of the clinical
manifestations of advanced cancer including fatigue, cachexia
and nutritional decline [17]. Moreover, in an exploratory
subanalysis of 8 subjects in whom pre and post treatment FDG-
PET scans were used as a pharmacodynamic endpoint, we
found that all patients displaying metabolic progression of
disease were categorized as having a persistently elevated NLR
following treatment. Conversely, the achievement of NLR
normalization was associated with an overall decrease or
stability in SUVmax values in 3 out of 4 subjects (Figure 2).
Such observation, although preliminary in nature, seems to
further substantiate the link between disease activity and
worsening of the inflammatory scores.
In our screening of prognostic traits the baseline NLR ranked
as the most informative variable in predicting early mortality
and followed patient’s PS as the second most accurate predictor
in estimating OS. Moreover, addition of the NLR to PS
significantly increased the discriminative ability of PS alone. In
particular, we noted that the an elevated NLR independently
predicted for worse survival outcome in patients with preserved
as well as more advanced PS (Table 4). This finding holds
significant implications in the screening process of phase I
candidates, as adequate PS (ECOG 0–2) and a predicted life
expectancy exceeding 90 days are the most clinically utilized
criteria in assessing the eligibility of patients with advanced
cancer considered for early phase trials. Based on our findings,
the NLR could therefore be usefully integrated with PS to
increase the overall accuracy of prognostic prediction in such a
heterogeneous patient population.
The prognostic impact of biomarkers of systemic inflamma-
tion has been left relatively unaddressed in early phase clinical
trial patients, despite previous reports highlighting the prognos-
tic value of individual determinants of ongoing inflammatory
reaction such as leukocytosis, neutrophilia, lymphopenia,
thrombocytosis and hypoalbuminemia in this patient population
[5,35,36,37].
One of the major limitations in the assessment of novel
prognostic models in patients with advanced cancer is the single-
institutional and retrospective nature of most studies [10], where
survival and eligibility rates can be inherently different across
institutions depending on the efficiency of the referral process
within each institution, the availability of clinical trial slots and
the presence of trial-specific eligibility criteria. A methodological
strength of our study comes from the evaluation of the NLR and
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Table 4. Integration of the NLR with ECOG PS in the prediction of OS (Training and Validation Set).
Training Set#
ECOG PS NLR N Median OS (months) 95% CI (months) P-value1
0 ,5 24 13.6 0.5–32.5 0.01*
$5 9 7.5 1.5–13.3
1 ,5 37 6.5 4.5–8.5
$5 15 5.4 3.5–7.4
2–3 ,5 8 2.5 0.5–6.2
$5 17 2.2 1.0–3.5
Validation Set##
ECOG PS NLR N Median OS (months) 95% CI (months) P-value1
0–1 ,5 36 6.7 6.1–7.4 0.05*
$5 24 4.7 3.5–5.9
2–3 ,5 4 4.7 4.4–5.0
$5 9 1.8 1.7–1.8
1Chi-square test of equality of survival distributions for the different NLR categories.
#Patients with PS 2 and 3 were considered together due to the small number of patients with PS = 3 (n = 9),
##Patients were dichotomized as ‘‘favourable PS’’ (ie. 0–1) versus ‘‘poor PS’’ (ie. 2–3) due to limited sample size.
*Marks an association reaching statistical significance (p,0.05).
doi:10.1371/journal.pone.0083279.t004
Figure 3. Exploratory subanalysis investigating the relationship between NLR normalization and 18FDG-PET SUVmax in patients
treated with a molecularly targeted IMP (n=8). Panel A: Waterfall plot showing individual metabolic responses in patients with normalized
versus persistently elevated NLR following treatment. Panel B: Representative PET-CT fused axial images obtained at screening and after 8 weeks of
treatment with an oral targeted agent. In patient 1 a 15% reduction of SUVmax in the region of interest is associated with NLR normalization
following treatment. In patient 2 metabolic progression of disease, with a 40% increase in SUVmax is associated with worsening of the NLR at the
time of disease reassessment.
doi:10.1371/journal.pone.0083279.g003
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PLR by means of cross-validation in an independently collected set
of patients in an attempt to reduce sampling bias and overcome
potential systematic error relating to the presence of missing data
[38]. Interestingly, our analysis showed that the NLR and its
dynamic changes following treatment are independent predictors
of survival in both the training and the validation set, therefore
strengthening the generalizability of this observation. Based on our
results, no prognostic role could be inferred for the PLR in patients
considered for phase I trials, suggesting that the NLR is a more
accurate biomarker of systemic inflammation.
In our study we could not assess the prognostic value of the
Glasgow Prognostic Score, since CRP was not routinely measured
in the majority of our patients. Because of the retrospective nature
of our study, we were unable to validate the NLR prospectively, an
approach that may be suggested in future studies, especially in
light of the relatively small sample size of our patient cohorts
compared with previously published retrospective studies involving
more than 2000 phase I study participants [39]. The significant
amount of missing data emerging for some of the variables we
analyzed needs to be taken into consideration as a limitation to our
study, strengthening the need for further prospective validation of
the NLR before systemic inflammation can be confidently applied
in the clinical arena. A further advantage of inflammation based
scores that will have to be explored in prospective studies relies on
their potential role in predicting toxicity from anticancer
treatments, which is largely contingent on an inflammation
induced impairment of cytochrome 3A activity [40] as well as
patients’ nutritional decline [41].
In conclusion, we have shown that inflammatory related
changes in common laboratory markers such as the NLR are
easy to compute, universally available, inexpensive and reproduc-
ible biomarkers that can be used in the prognostic assessment of
potential phase I candidates as well as in the prediction of clinical
benefit from experimental treatments.
ECOG-PS is a largely utilized screening tool and remains the
gold standard prognostic determinant in patients with advanced
cancer [6,36,37,42]. Here we provide preliminary evidence that
the NLR can be easily combined with ECOG-PS to achieve an
improved and more objective estimation of patient’s prognosis.
Given that our study included consecutive phase I referrals, our ad
hoc sub-analysis was not powered to explore the relationship
between each ECOG-PS stratum and the NLR, leading to the
need to combine prognostic strata and to subgroup patients in
broader categories including ‘‘favorable’’ (ie. 0–1) versus ‘‘poor’’
(ie. 2–3) PS, a limitation that should addressed prospectively.
Indeed, the magnitude of the prognostic improvement emerging
by the combination of ECOG-PS and NLR is modest based on
our c-index analysis. Nonetheless, our study promotes the concept
of a concurrent assessment of patients’ PS and systemic
inflammatory status, two independent and non-mutually exclusive
prognostic domains whose combined evaluation should be further
explored in future, adequately powered clinical studies. Taken
together, our results promote the use of the NLR as a universally
available biomarker to optimize the eligibility assessment of
patients with advanced cancer considered for phase I trials and
serve as an early predictor of response to experimental treatments.
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